Who are Levofloxacin intravenous solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levofloxacin film-coated tablet, Moxifloxacin (Avelox), Moxifloxacin (M), Moxifloxacin Injectable Product, gatifloxacin ophthalmic solution 0.3%, levofloxacin-based sequential therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin-intravenous-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Levofloxacin intravenous solution — Competitive Intelligence Brief

Levofloxacin intravenous solution (Levofloxacin intravenous solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic. Area: Infectious Disease.

marketed Fluoroquinolone antibiotic DNA gyrase; Topoisomerase IV Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Levofloxacin intravenous solution (Levofloxacin intravenous solution) — Mackay Memorial Hospital. Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levofloxacin intravenous solution TARGET	Levofloxacin intravenous solution	Mackay Memorial Hospital	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Levofloxacin film-coated tablet	Levofloxacin film-coated tablet	Mackay Memorial Hospital	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin (Avelox)	Moxifloxacin (Avelox)	Connect Biopharma Australia Pty Ltd	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin (M)	Moxifloxacin (M)	Global Alliance for TB Drug Development	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin Injectable Product	Moxifloxacin Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
gatifloxacin ophthalmic solution 0.3%	gatifloxacin ophthalmic solution 0.3%	Allergan	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
levofloxacin-based sequential therapy	levofloxacin-based sequential therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase; topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic class)

Bayer · 4 drugs in this class
Allergan · 4 drugs in this class
Mackay Memorial Hospital · 2 drugs in this class
Indiana University School of Medicine · 2 drugs in this class
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Connect Biopharma Australia Pty Ltd · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Global Alliance for TB Drug Development · 1 drug in this class
Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levofloxacin intravenous solution — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-intravenous-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab